Anemarsaponin E is extracted from Anemarrhena asphodeloides Bunge and has anti-inflammatory activity.

Angiotensin (1-7) (Ang-(1-7)) is an active heptapeptide of the Renin-angiotensin system (RAS), inhibits purified canine angiotensin converting enzyme (ACE) activity with IC50 of 0.65 uM.

Angiotensin II human is a peptide hormone that causes vasoconstriction and a subsequent increase in blood pressure.

Anguizole is a HCV NS4B inhibitor targeting second amphipathic helix of NS4B (NS4B-AH2), blocks genotype 1b HCV replication with EC50 of 310 nM.

Anidulafungin

ANT431 is a novel potent metallo-β-lactamase (MBL) inhibitor with IC50 of 290 nM and 195 nM for NDM-1 and VIM-2, shows a comparatively weak inhibitor of VIM-1 and IMP-1 (Ki of 14.6 and 4.15 uM, respectively).

ANT431 sodium is a novel, highly water-soluble metallo-β-lactamase (MBL) inhibitor with IC50 of 290 nM and 195 nM for NDM-1 and VIM-2, shows a comparatively weak inhibitor of VIM-1 and IMP-1 (Ki of 14.6 and 4.15 uM, respectively).

Antimalarial compound 49c is a potent antimalarial peptidomimetic inhibitor originally developed against Plasmepsin II selectively targets TgASP3, PfPMIX, and PfPMX, shows very potent antimalarial effects only after 72 h of treatment with IC50 of 0.6 nM.

Antimycin A is an inhibitor of cellular respiration, specifically oxidative phosphorylation, binds to the Qi site of cytochrome c reductase, disrupts the Q-cycle of enzyme turn over.

Antipyrine is an analgesic and antipyretic agent

ANY1 (FosA inhibitor ANY1) is a small molecule active site inhibitor of FosA (metal-dependent glutathione S-transferase) with IC50 of 5.1 uM (K. pneumoniae FosA).

AP1867 is a synthetic FKBP12F36V-directed ligand.

AP1903 (Rimiducid, AP-1903) is a potent, specific synthetic ligand of FKBP Phe36Val mutant (F36V-FKBP) with binding IC50 of 1.8 nM.

AP219 is a control compound for AP39, containing the triphenylphosphonium scaffold but lacking the H2S-releasing portion.

ALK-IN-1 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1.

APA modulator T4 is a small modulator of alternative polyadenylation (APA) with IC50 of 2.1 uM in reporter assays, modulates endogenous APA via nonkinase-mediated pathways and promotes distal-to-proximal (DtoP) APA usage in multiple transcripts.

APA modulator T5 is a small modulator of alternative polyadenylation (APA), modulates endogenous APA via nonkinase-mediated pathways and promotes distal-to-proximal (DtoP) APA usage in multiple transcripts.

Apararenone (MT-3995) is a novel potent, selective non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis..

Apatinib is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities.

Apcin is a cell-permeable, small molecule anaphase-promoting complex/cyclosome (APC/C) inhibitor, which binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates.

APD597(JNJ-38431055) is a GPR119 agonist intended for the treatment of type 2 diabetes, with EC50 of 46 nM for hGPR119.

APD916 is a potent and selective antagonist of the H3 receptor with Ki of 0.7 nM for rH3R.

apelin receptor.

Apicidin (OSI 2040) is a fungal metabolite that exhibits potent, broad spectrum antiprotozoal activity in vitro, potently inhibits HDAC with IC50 of 0.7 nM in an enzyme activity assay.

Apilimod(STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, IL-12 production in cultures of IFN-r/LPS–stimulated human PBMCs is strongly inhibited by STA-5326 with an IC50 of 10 nM.

Aplaviroc (GSK-873140.

Aplaviroc, also known as AK-602; GW-873140; GW873140A; ONO-4128, is a CCR5 entry inhibitor for the potential treatment of HIV infection. Aplaviroc (GW873140) binds specifically to human cellular CC chemokine receptor 5 (CCR5) and demonstrates potent anti-human immunodeficiency virus activity in vitro in the subnanomolar range. In vitro studies show that aplaviroc selectively inhibits the binding of a particular monoclonal antibody, 45531, to CCR5.

Apogossypol (NSC 736630) is a Bcl-2 family antagonist that binds to Bcl-XL, Bcl-2 and Bcl-xL with IC50 of 2.6, 2.8 and 3.69 uM, respectively.

Apomorphine hydrochloride hemihydrate is a non-selective dopamine agonist which activates both D1-likeand D2-like receptors, with some preference for the latter subtypes..

Apoptozole is an inhibitor of heat shock protein 70 (Hsp70; 65% inhibition at 200 μM) that acts by blocking its ATPase activity.

Apricitabine is a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs

Aprotinin is a serine protease inhibitor isolated from bovine lung which inhibits trypsin and chymotrypsin with Ki values of 0.06 pM and 9 nM, respectively.

APS-3-77 is the negative binder of KSR2.

APTO-253 is a small molecule inducer of KLF4, stabilizes G-quadruplex DNA and reduces MYC mRNA expression and protein levels.

APX001 (APX 001A;E1210) is a novel broad-spectrum antifungal agent that inhibits the fungal protein Gwt1, demonstrates significantly acitive MIC50 and MIC90 values of 0.004 and 0.031 ug/ml (16 strains of C. auris).

APX2009 (APX-2009) is a novel potent inhibitor of reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1) with IC50 of 0.45 uM for redox EMSA inhibition.

APX2014 (APX-2014) is a novel potent inhibitor of reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1) with IC50 of 0.2 uM for redox EMSA inhibition.

AQ-101 is a novel small-molecule anthraquinone analog that induces MDM2 protein degradation (Kd=0.37 uM) through a self-ubiquitination and proteasome-mediated mechanism, leading to activation of p53.

AQ-13 dihydrochloride is an aminoquinoline antimalarial drug that is effective against chloroquine-resistant strains of Plasmodium falciparum.

AQW-051 is a novel, potent and selective, orally bioavailable, brain-penetrant α7 nAChR partial agonist with pKd of 7.56.

AQX 1125 (Rosiptor) is a specific, orally bioavailable SHIP1 activator.

AR03 (AR-03, AR 03, Ape1 repair inhibitor 03) is a novel small molecule inhibitor of DNA repair protein apurinic/apyrimidinic endonuclease 1 (APE1) endonuclease activity with IC50 of 5 uM.

AR231453 is a potent and selective small molecule agonist of GPR119 that enhances glucose-dependent insulin secretion and glucagon-like peptide 1 (GLP-1) release; Antidiabetic agent.

ARA-290 (Cibinetide) is a non-erythropoietic erythropoietin (EPO) derivative.

Ara-G (9-β-D-Arabinofuranosyl guanine) is an inducer of apoptosis, inhibitor of DNA synthesis, an antimetabolite, and antineoplastic.

Aramchol, also known as arachidyl amido cholanoic acid, is a conjugate of arachidic acid and cholic acid.

Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational HIV therapies. Arbidol hydrochloride (Umifenovir hydroc

AR-C102222 is a potent, selective iNOS inhibitor with IC50 of 35 nM, dislapys 3,000-fold and 20-fold selectivity over eNOS and nNOS respectively.

AR-C155858 is a potent monocarboxylate transporter MCT1 and MCT2 with Ki of 2.3 nM and <10 nM, displays no activity at MCT4.

Arctigenin is an extract from A. lappa, a burdock plant traditionally used in Japanese Kampo medicine for its antioxidant, anti-inflammatory,

Arctiin, a plant lignan that can be extracted from the Arctium lappa (burdock) seeds, is a possible environmental endocrine disruptor compounds and have been shown to influence sex hormone metabolism as well as protein synthesis, steroid biosynthesis.

Arg-AMS is a potent nanomolar inhibitor of arginyl tRNA synthetase, which displays tightly bound inhibitory characteristics for the A-domains in non-ribosomal peptide synthetases (NRPS) enzymes.

Argatroban

Argatroban monohydrate is a direct, selective thrombin inhibitor.

Arglabin is a sesquiterpene gamma-lactone is isolated from Artemisia glabella; anticancer natural compound.

AR-HO47108 is a potent, selective acid pump antagonist (potassium-competitive acid blocker or P-CAB) that reversiblely inhibits gastric H+/K+-ATPase with pIC50 of 7.0.

ARM390 is a non-peptidic, low-internalizing δ-selective opioid receptor agonist.

ARN077 is the first potent, selective N-acylethanolamine acid amidase (NAAA) inhibitor with IC50 of 7 nM on both rat NAAA and human NAAA.

ARN14494 (ARN-14494) is a potent, small molecule serine palmitoyltransferase (SPT) inhibitor with IC50 of 27.3 nM.

ARN19874 (ARN-19874) is the first selective, cell-active inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) with IC50 of 33.7 uM.

ARN-3261 is a potent, selective, orally available salt inducible kinase SIK2 and SIK3 inhibitor with IC50 of 11 nM and 19 nM, respectively.

ARN726 is a potent, selective, orally bioavailable N-acylethanolamine acid amidase (NAAA) inhibitor with IC50 of 63 nM (r-NAAA) and 27 nM (h-NAAA).

ARP101 (ARP-101) is a selective MMP-2 inhibitor, induces autophagy-associated cell death in cancer cells.

ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1.

ARRY-502 is an orally bioavailable, potent and selective antagonist of the prostaglandin D2 receptor (CRTh2) for treatment of mild to moderate Th2-driven asthma..

ARRY-520 is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM.

ARRY-520 R enantiomer is the R form of ARRY-520, which is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM.

Artefenomel (OZ439) is a novel, next-generation antimalarial ozonide that demonstrates high potentcy against P. falciparum in vitro and P. berghei in vivo (K1/NF54, IC50=2.0/3.2 nM)..

Arterolane (OZ277.

Articaine is a dental local anesthetic which contains an additional ester group that is metabolized by estearases in blood and tissue.

Arylsulfonamide 64B (HIF inhibitor 64B) is a small molecule HIF pathway inhibitor, blocks hypoxia-induced expression of c-Met and CXCR4 and uveal melanoma (UM) cell migration.

AS 2553627 (AS2553627) is a novel potent, selective pan-JAK inhibitor with IC50 of 0.46, 0.30, 0.14 and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively.

AS-1269574 is a selective, orally available GPR119 agonist with EC50 of 2.5 uM in cell-based cAMP assays.

AS1928370 (ASP8370) is a potent, selective, orally available TRPV1 antagonist with IC50 of 0.51 uM, shows no inhibitory effects on TRPV4, TRPA11, and TRPM8 at 10 uM.

AS-1949490 (AS1949490) is a potent, selective SHIP2 inhibitor with IC50 of 0.34/0.62 uM for mouse/human SHIP2.

AS2521780 is a potent, selective, orally bioavailable PKCθ inhibitor that inhibits combinant human PKCθ enzyme with IC50 of 0.48 nM, >30-fold higher than other PKC isoforms.

AS-252424 is a novel, potent and selective inhibitor of PI3Kγ with IC50 of 33 nM.

AS2541019 is a novel potent, selective, orally active PI3Kδ inhibitor with IC50 of 20.1 nM, >100-fold selectivity over other PI3K isoforms.

AS2677131(AS 2677131, AS-2677131) is a novel potent, oral PIKfyve inhibitor that selectively decreases c-Rel binding to gene promoters of IL-12p40 and IL-1β, regulates cytokine production through PIKfyve-c-Rel pathway ( IL-12p40 IC50=4 nM).

AS2717638 is an oral active lysophosphatidic acid receptor 5 (LPA5) antagonist in rodents. AS2717638 also significantly improves PGE2-, PGF2α-, and AMPA-induced allodynia.

AS-604850 is a selective, ATP-competitive PI3Kγ inhibitor with IC50 of 250 nM, over 80-fold selectivity for PI3Kγ than PI3Kδ/β, and 18-fold more selective for PI3Kγ than PI3Kα.

Asapiprant (BGE-175) is a potent and specific antagonist of human PGD2/PTGDR signaling with Ki of 0.44 nM. BGE-175 is currently in a Phase 2 clinical trial to test whether it can prevent disease progression and mortality in older patients hospitalized wit

Asciminib (ABL-001) is a potent and selective allosteric ABL1 inhibitor with IC50 of 0.25 nM in BCR–ABL1-transformed BaF3 cells.

Ascomycin is an analog of tacrolimus with immunosuppressive, neurotrophic and antifungal activities.

Ascorbyl palmitate is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C.

Asimadoline (EMD-61753) is a drug which acts as a peripherally selective κ-opioid receptor (KOR) agonist.

ASN-002 (Gusacitinib, ASN002) is a novel and potent dual inhibitor of SYK/JAK kinases with IC50 of 5-46 nM in biochemical assays.

ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.

ASP5878 is a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.

ASP6432 (ASP-6432) is a potent and selective antagonist of LPA1 receptor, does-dependently inhibits LPA-stimulated increase in intracellular calcium ion with IC50 of 11 nM.

ASP9436 (ASP-9436) is a potent, selective brain penetrant and orally active phosphodiesterase 10A (PDE10A) inhibitor with IC50 of 8.0 nM, >420-fold selectivity over other PDE subtypes.

ASP-9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC50 of 11 nM for human AKR1C3.

Aspacytarabine (Astarabine, BST236) is a cytarabine conjugate that shows anti-​neoplastic agents for inhibiting cancer cell growth. .

Asp-AMS, an analogue of aspartyl-adenylate, is an aspartyl-tRNA synthetase inhibitor and also a strong competitive inhibitor of the mitochondrial enzyme.

Aspartame

Astaxanthin, a red dietary carotenoid isolated from Haematococcus pluvialis, is an inhibitor of PPARγ and a potent antioxidant with antiproliferative, neuroprotective and anti-inflammatory activity. Astaxanthin has potential in the treatment of various di

Astex ERK inhibitor X is a novel potent ERK1/2 inhibitor that inhibits ERK catalytic activity with IC50 of 3 nM in TRK kinase assays.

Astin C is a cyclopeptide isolated from the medicinal plant Aster tataricus, inhibits cGAS-STING signaling and the innate inflammatory responses triggered by cytosolic DNAs, inhibits intracellular DNA-induced Ifnb expression with IC50 of 3.42 and 10.83 uM

Astragaloside A, also known as astragaloside IV, is known to have diverse protective effects for the cardiovascular, immune, digestive, and nervous systems.

Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing.

ASTX660 hydrochloride is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.

ASTX660 is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.

ASTX660 mesylate is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.

Asunaprevir (BMS-650032) is a potent hepatitis C virus (HCV) NS3 protease inhibitor.

AT-090 is a novel potent, selective nociceptin/orphanin FQ receptor (NOP receptor) agonist with Ki of 5.61 nM.

AT-1002, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer.

AT-127 is a novel potent, selective nociceptin/orphanin FQ receptor (NOP receptor) agonist with Ki of 1.18 nM.

AT-130 is a potent inhibitor of HBV capsid assembly, inhibits wild-type HBV replication with IC50 of 2.4 uM.

AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity; AKT, p70S6K, PKA, ROCK, and SGK inhibitor.

AT-403 (AT403) is a potent, highly selective, nonpeptide NOP agonist with pEC50 of 9.45.

AT-406 (formerly known as SM-406) is an orally bioavailable potent IAP (inhibitor of apoptosis protein) of XIAP, cIAP1, and cIAP2 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, respectively.

AT791 is a novel orally available, small molecule inhibitor of TLR7 and TLR9 with IC50 of 3.33 uM and 0.04 uM respectively, inhibits DNA-TLR9 interaction in vitro.

Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC.

Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC.

Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia..

ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity.

Atglistatin is a highly potent, selective and competitive inhibitor of adipose triglyceride lipase (ATGL) with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, but no toxicity up to a concentration of 50 μM.

Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways.

Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways.

ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0

ATM-3507 (ATM3507) is a small molecule inhibitor of Tpm3.1 tropomyosin isoform, disrupts Tpm3.1-containing microfilaments in SK-N-SH cells at 5 uM.

ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.

Atocalcitol

Atomoxetine ((R)-Tomoxetine.

Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.

ATP (Adenosine-Triphosphate)

ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM.

ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM.

Atractylenolide II has antiinflammatory activity, it can inhibit platelets activities and thrombus formation. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation ,ERK and Akt inactivation, p53 dependent, it also has antimelanoma effe

Atractylenolide III, a potential house dust mite control agent, has neuroprotection, gastroprotective, anti-cancer, and anti-inflammatory activities, it also may control immunological reactions by regulating the cellular functions of IL-6 in mast cells.

Atractylone has inhibitory effects on mast cell-mediated allergic reactions, it regulates the degranulation of mast cell, proves its potential in the treatment of mast cell-mediated allergic reactions.

Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.

ATV399 (ATV-399) is a novel small molecule that dose-dependently reduces the cleaved caspase9 levels with IC50 of 3.3 uM, inhibits dimerization of iNOS.

ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes.

AU1 (GSK 1379725A) is the first selective small molecule inhibitor of BPTF bromodomain (bromodomain PHD finger transcription factor) with Kd of 2.8 uM in a cell-based reporter assay, shows no binding activity for Brd4.

Aumitin is a novel potent autophagy inhibitor with IC50 of 124 and 244 nM against starvation- and rapamycin- induced autophagy respectively, targets mitochondrial complex I.

AUNP-12 (Aurigene-012) is a PD-1 inhibitor peptide, blocks the PD-1/PD-L1, PD-1/PD-L2 and PD-L1/CD80 pathways.

Aurantiamide acetate suppresses the growth of malignant gliomas in vitro and in vivo by inhibiting autophagic flux.

Aurintricarboxylic acid (ATA) is a potent small molecule inhibitor of RISC loading with IC50 of 0.47 uM, inhibits RISC activity against transiently expressed reporters and endogenous genes.

Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates.

Aurora inhibitor 1 is a potent Aurora inhibitor with an IC50 of ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase, respectively.

Aurora kinase inhibitor III is a potent inhibitor of Aurora A kinase (IC50 = 42 nM).

Autotaxin inhibitor 12 is a highly potent, selective, orally-bioavailable inhibitor of autotaxin with IC50 of 3.1 nM in choline release assays.

Autotaxin inhibitor compound 1 (Autotaxin-IN-1) is a potent, selective, orally bioavailable inhibitor of autotaxin with IC50 of 2.2 nM in ex vivo human whole blood assay, does not inhibit related proteins ENPP1 and ENPP7.

Auxin agonist RN3 (RubNeddin 3) is a potent, selective auxin agonist that induces specific AUX/IAA protein degradation to modulate plant development.

Auxin agonist RN4 (RubNeddin 4) is a potent, selective auxin agonist that induces specific AUX/IAA protein degradation to modulate plant development.

Avanbulin (BAL27862, BAL-27862) is a novel microtubule-destabilizing agent that potently inhibits tubulin assembly at 37°C with IC50 of 1.4 uM in tubulin-binding assays.

Avasimibe inhibits ACAT and CYP2C9 with IC50 of 3.3 μM and 2.9 μM, respectively.

AVE-0118 is a potent I(to)/I(Kur) blocker, Kv1.5 channel inhibitor with IC50 of 5.6 uM, also blocks Kv1.3, Kv2.1, Kv3.1, and Kv4.3 channels with similar potency.

AVex-73 is a muscarinic M1 agonist potentially for the treatment of Alzheimer's disease

AVG-233 (AVG233) is a potent, allosteric inhibitor of respiratory syncytial virus (RSV) RNA-dependent RNA polymerase (RdRp) complex, demonstrates nanomolar activity against both laboratory-adapted RSV strains and clinical RSV isolates (EC50=34-79 nM).

Avibactam sodium(NXL-104) is a non-β-lactam β-lactamase inhibitor antibiotic.

AVL-292 besylate (Spebrutinib, CC-292) is a highly selective, covalent Btk inhibitor with IC50 of <1 nM.

AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2.

Avobenzone(Parsol 1789)

AVP-786 is a novel, next-generation investigational drug product consisting of a combination of deudextromethorphan, and an ultra-low dose of quinidine.

AW-814141 is a potent, selective and orally active inhibitor of p38 MAP kinase with IC50 of 100 nM/158 nM for p38α/p38β.

AWD 131-138(Imepitoin) is a new low-affinity partial benzodiazepine receptor agonist with potent anticonvulsant and anxiolytic properties in rodent models.

AWZ1066S is a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis.

AX20017 is a small-molecule protein kinase G (PknG) inhibitor with an IC50 of 0.39 μM.

Axl-IN-21 is a selective and potent inhibitor of wild-type Axl with IC50 of 2.2 nM.

AY 9944 is a specific cholesterol biosynthesis inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme (IC50=13 nM). AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol.

AY-NH2 is a peptide agonist of proteinase-activated receptor 4 (PAR4) that induces aggregation of rat and human platelets in vitro (EC50s = 15 and 60 μM, respectively).

AZ 4800 is a potent γ-secretase modulator that reduces Aβ40 and Aβ42 levels in HEK/APPswe cells with IC50 of 26 nM and 60 nM, also decreases Aβ39, whereas increases both Aβ37 and Aβ38..

AZ0108 is an orally bioavailable phthalazinone PARP inhibitor with enzyme IC50 of <30/<30/83 nM for PARP1/2/6 respectively.

AZ-1 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity.

AZ10606120 is a potent, specific P2X7 receptor antagonist with Kd of 1.4 and 19 nM at human and rat P2X7 receptors respectively.

AZ12204657 (AZ-12204657) small-molecule GPR44 antagonist, displaces the binding of [3H]PGD2 from membranes of HEK293 cells transfected with human recombinant GPR44 with IC50 of 2.5 nM.

AZ12441970 is a selective TLR7 agonist with pEC50 of 6.8 and 6.6 for human and rat TLR7, shows inactivity against TLR8.

AZ12601011 (AZ-12601011) is a potent, selective inhibitor of ALK4, ALK7 and TGFBR1 (Kd=2.9 nM), inhibits TGFβ-induced reporter activity with IC50 of 18 nM.

AZ12799734 (AZ-12799734) is a pan BMP/TGFβ inhibitor that potently inhibits ligand activated SMAD3/4 transcription with IC50 of 47 nM, inhibits receptor-mediated phosphorylation of SMAD1 by ALK1, BMPR1A and BMPR1B and phosphorylation of SMAD2 by ALK4, TGF

AZ-1355 is an effctive lipid-lowering compound that inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro..

AZ13705339 is a potent, selective PAK1 inhibitor with IC50 of 0.33 nM, displays 14-, 470-, 4100- and 2600-fold selectivity over Src, FGFR1, KDR and PAK4.

AZ13711265 is a potent, selective, in vivo active PAK1 inhibitor with IC50 of 0.58 nM, displays 880-, 2100- and 90-fold selectivity over Src, FGFR1, KDR and PAK4.

AZ1729 is a novel direct, positive allosteric modulator of fatty acid receptor FFA2 (pEC50=6.9), selectively activates Gi signaling but lacks the capacity to activate FFA2 Gq/G11-mediated signaling pathways.

AZ-2 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity.

AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM, 8-fold selectivity over mTOR.

AZ-23 is a potent, selective, orally bioavailable Trk kinase inhibitor with IC50 of 2 and 8 nM for TrkA and TrkB, respectively.

AZ-33 is a inhibitor of LDH-A with an IC50 of 0.5 μM.

AZ-4217 is a potent and selective, orally active, brain-permeable BACE1 inhibitor with IC50 of 160 pM in human SH-SY5Y cells.

AZ505 ditrifluoroacetate is a potent and selective SMYD2 inhibitor with IC50 of 0.12 μM.

AZ-7371（DprE1-IN-1） is a novel non-covalent DprE1 inhibitor.

AZ876 is a novel high-affinity LXR agonist.

AZ8838 racemate(AZ-8838 racemate) is the racemate form of AZ8838, which is a potent, and selective PAR2 antagonist with Kd of 125 nM..

Azathioprine (Azasan, Imuran) is the analytical standard of Azathioprine. This product is intended for research and analytical applications. Azathioprine (BW 57-322) is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces apoptosis.

AZD 0424 is an orally bioavailable small molecule tyrosine kinase inhibitor of Abl and Src kinase with potential antineoplastic activity..

AZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4.

AZD 3043 (THRX-918661) is a positive allosteric modulator of the GABAA receptor in vitro and a sedative/hypnotic agent in vivo, potentiates GABAA receptor-mediated chloride currents with EC50 of 36 uM.

AZD 4205 (AZD4205) is a potent, selective JAK1 inhibitor IC50 of 73 nM and Ki of 2.8 nM, shows high selectivity against JAK2 and JAK3 with IC50 of 13,233 nM and >30,000 nM respectively; shows potent inhibition of p-STAT3 in a cell based assay of JAK1 activity with an IC50 of 128 nM and excellent selectivity across the kinome; reduces residual disease and prolongs the benefit of Osimertinib in lung cancer patients with EGFR activating mutations both in vitro and in vivo.

AZD 5991 (AZD5991) is a potent and selective macrocyclic inhibitor of Mcl-1 with sub-nanomolar affinity.

AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus..

AZD 7009 is a novel antiarrhythmic agent that inhibits the late sodium current in CHO K1 cells expressing hNav1.5 with IC50 of 11 uM.

AZD0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.

AZD-0837 is a novel oral anticoagulant that after bioconversion to its active form is a potent and reversible thrombin inhibitor, has been investigated in phase II studies for prevention of stroke and systemic embolic events in patients with atrial fibril

AZD0865 is a potent agent that inhibits gastric H(+),K(+)-ATPase activity and acid formation in vitro, with a fast onset of effect.

AZD-1092 (GKA-80) is a potent Glucokinase (GK) activator with EC50 of 30 nM.

AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.

AZD-1305 is a novel antiarrhythmic agent that predominantly blocks the rapid component of IKr, the L-type calcium current, and the inward sodium current in mammalian cells and ventricular cardiomyocytes.

AZD1390 is a first-in-class orally available and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cells and >10,000-fold selectivity over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases

AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms (α/β/γ/δ).